Amgen adopted perfusion for smaller, intense factories of the future, while Genentech, with existing large reactors, had no incentive. This shows technology adoption is dictated by a company's unique strategic drivers and infrastructure, not just the technology's superiority.
A technology's success isn't just about high-level metrics like facility output. If the product is inconvenient or frustrating for the end-user—the scientist at the bench—it will face strong resistance and likely fail, regardless of its theoretical benefits. User experience is paramount.
Instead of planning a specific exit, founders should first decide what kind of life they want. Do you want to run a large company or sell early? Answering this personal question is the first step, as founder happiness and alignment are critical to the company's success and longevity.
John Bonham-Carter commercialized the ATF system, invented by the "crazy" Jerry Schovitz. He emphasizes that his role was to execute on someone else's failing vision, highlighting the need for both a radical inventor and a pragmatic business leader to bring a product to market.
John Bonham-Carter built his extensive network by traveling 150-200 days a year for nearly five years, personally meeting over 8,000 people. This highlights that deep, influential industry relationships are forged through relentless in-person engagement, a strategy digital networking cannot fully replace.
John Bonham-Carter's grandmother ran a bioreactor company, and he spent weekends at the facility as a child. This early, immersive exposure to the industry and the entrepreneurial lifestyle created a foundational understanding and comfort with risk that influenced his entire career.
When joining Refine Technology, John Bonham-Carter accepted a small salary for a share of the company. He frames this as a risk-based trade—income for equity—that is particularly viable for younger professionals who can afford the financial risk, potentially leading to significant long-term rewards.
